Mitochondria are organelles that contain their own genomes (mtDNA) however, the majority of the mitochondrial proteome is encoded by nuclear genes and imported into the mitochondria for assembly into various components. Mitochondria adapt metabolism and biomass to changes in cellular protein synthesis rates accompanying growth. The signaling mechanisms that precede or initiate a mitochondrial expansion program to coordinate mitochondria-to-nuclear communication during development is not well-understood. C. elegans undergo long bouts of starvation in their natural environment upon hatching and remain developmentally arrested as L1s (also known as “L1 diapause”) until they encounter food sources. Prolonged L1 diapause leads to manifestation of age-related phenotypes and mitochondrial remodeling. The mitochondrial unfolded protein response (UPRmt) is a transcriptional response mediated by the bZip protein ATFS-1. ATFS-1 scales mitochondrial expansion with protein synthesis during normal development by regulating genes involved in mitochondrial biogenesis. Here, we demonstrate that ATFS-1 is required for growth and establishment of mature germline upon exiting from starvation-induced L1 arrest. Starvation survival as well as mtDNA depletion during L1 arrest is independent of ATFS-1. Interestingly, we found that the mitochondrial-localized function of ATFS-1 is required for the recovery and expansion of mtDNA following feeding. Lastly, we demonstrate that ATFS-1 functions downstream of the insulin-IGF signaling pathway to regulate mtDNA quantity. The insulin receptor DAF-2 senses nutrient fluctuations and hypomorphic mutation in DAF-2 causes an increase in mtDNA level partly regulated by mitochondrial-localized ATFS-1. Together, our data indicate the physiological relevance and significance of UPRmt in recovering mitochondrial mass when growth and development resumes following starvation.

Dans la plupart des pays industrialisés, le cancer du sein est la principale cause de décès chez les femmes. Le microenvironnement tumoral (TME) joue un rôle important dans la progression du cancer du sein. Le TME est un tissu complexe composé d’une matrice extracellulaire remaniée, de fibroblastes, de cellules inflammatoires et endothéliales. Récemment un nouveau composant cellulaire du TMA a été identifié. Il est formé par des adipocytes modifiés situés en regard de cellules cancéreuses appelées "adipocytes associés au cancer" (CAA). Ces constituants ajoutent à la complexité du TME. La protéase matricielle Matrix Metalloproteinase-11 (MMP-11) est une protéine du TME, elle est sécrétée par les «fibroblastes associés au cancer» (CAF) au centre de la tumeur et par les CAA à la périphérie de la tumeur (le front d’invasion). Soutenant l'idée que la MMP11 contribue à la progression tumorale, des études antérieures ont montré qu’une expression élevée était associée à une survie sans récidive plus courte des patientes atteintes d'un cancer du sein. Cependant, le mécanisme d'action spécifique de cette protéase est resté mal compris. Des études plus récentes ont montré que la MMP-11 est un régulateur négatif du développement du tissu adipeux et qu’elle module le métabolisme énergétique. Ces observations suggéraient que l'expression de MMP-11 dans le TME pourrait participer directement à la progression de la tumeur en modulant le métabolisme du tissu adipeux au profit des cellules cancéreuses. Cependant, la façon dont la MMP-11 agit, notamment à l'interface entre les cellules cancéreuses du sein et les CAAs, reste largement inconnue. Pour l’étudier, nous avons développé des modèles précliniques de cancer de la glande mammaire chez la souris par génie génétique. Tout d'abord, des souris déficientes (perte de fonction-LOF) ou surexprimant MMP-11 (Gain de Fonction-GOF) ont été croisées avec un modèle génétique de tumeurs mammaires (MMTV-PyMT). Des résultats cohérents ont été obtenus en utilisant les deux modèles. La MMP11 favorise la progression tumorale précoce, en augmentant la prolifération et en réduisant l'apoptose des cellules cancéreuses. De plus, l’expression de la MMP-11 a été associée à un changement métabolique dans la tumeur et à une altération significative de l’Unfolded Protein Response mitochondriale (UPRmt) et à une activation du stress du réticulum endoplasmique (UPRER). Ces données confortent l'idée selon laquelle la MMP-11 contribue à une réponse métabolique adaptative favorisant la croissance du cancer. Deuxièmement, pour aborder directement la fonction de la MMP-11 produite par le tissu adipeux sur la progression du cancer, nous avons généré une lignée de souris transgénique (appelée aP2-MMP11-IRES-GFP) dans laquelle l'expression de MMP-11 est contrôlée par un promoteur spécifique du tissu adipeux. L’implantation directe de cellules cancéreuses syngéniques dans le coussinet mammaire de ces souris a montré que l'expression de la MMP11 favorisait la croissance tumorale. Finalement, nos données soutiennent le concept selon lequel l'expression de MMP-11 par les adipocytes associés au cancer (CAA) contribuerait à une réponse métabolique adaptative favorisant la croissance du cancer. Ils renforcent aussi l’intérêt que représente la MMP-11 comme cible pour le traitement du cancer. / Breast cancer is the most common leading cause of death in women. The tumor microenvironment (TME) plays an important role in breast cancer progression. The TME is a complex tissue composed of extracellular matrix proteins, fibroblasts, inflammatory and endothelial cells. Recently modified adipocytes called “Cancer-Associated Adipocytes” (CAAs) were identified as emerging components of the TME adding into the complexity of this tumor component. Matrix Metalloproteinase-11 (MMP-11) is a protein from the TME, it is secreted by "Cancer-Associated Fibroblasts" (CAFs) in the center of the tumor and by CAAs in the tumor periphery also qualified as the “invasive front”. Previous studies showed that elevated MMP11 expression is associated with a poorer outcome in breast cancer patients supporting the idea that MMP11 contributes to tumor progression but the mechanism of action remained unclear. Recent studies showed that MMP-11 is a negative regulator of adipose tissue development and controls energy metabolism. These observations suggested that MMP-11 expression in the TME may directly participate in breast tumor progression by modulating the adipose tissue metabolism at the benefit of cancer cells. However, how MMP-11 acts in the TME notably at the interface of breast cancer cells and CAAs remains largely unknown. To study the role of MMP-11 on breast cancer progression, we developed a series of preclinical mouse mammary gland tumour models by genetic engineering. First, mice either deficient- (Loss of Function-LOF) or overexpressing- MMP-11 were crossed with a genetic model of spontaneous mammary tumors (MMTV-PyMT). Consistent results were obtained using GOF and LOF, showing that MMP11 favored early tumor progression, by increasing proliferation and reducing apoptosis of cancer cells. Of interest, MMP-11 was associated with a metabolic switch in the tumor and the activation of the mitochondrial unfolded protein response (UPRmt) and endoplasmic reticulum stress (UPRER). These data support the idea that MMP-11 contributes to an adaptive metabolic response favoring cancer growth. Second, to directly address the function of MMP-11 produced by the adipose tissue on cancer progression, we generated a transgenic mouse line (named aP2-MMP11-IRES-GFP) in which MMP-11 expression is controlled by an adipose tissue-specific promoter. Direct grafting of syngeneic cancer cells in the mammary fad-pad of these mice showed that MMP11 expression favored tumor growth. Altogether our data support the idea that MMP-11 expression by cancer associated adipocytes contributes to an adaptive metabolic response, named metabolic flexibility, favoring cancer growth. They further substantiate the potential of MMP-11 as a target for cancer therapy.

With age comes a decline in the dynamic regulation of a balanced and functional mitochondrial proteome (proteostasis) that leads to an increase in oxidative stress and macromolecule damage, with a decline in ATP production. Compromised protein networks and reduced available energy leaves an organism susceptible to accelerated aging and the onset of age-related disease. Since mitochondrial respiratory complexes are composed of protein subunits from both mitochondria and nuclear genomes, their assembly relies on the coordination of mitochondrial and cytoplasmic translation machinery. Disruption of mitochondrial translation generates an imbalance in the ratio of mitochondrial (mtDNA) to nuclear DNA (nDNA) encoded proteins, which is called a mitonuclear protein imbalance. In response to the protein imbalance, a retrograde stress signal is sent from the mitochondria to the nucleus, invoking the mitochondrial unfolded protein response (UPRᵐᵗ) to resolve the mitoproteostatic stress. In a young healthy cell, the UPRᵐᵗ upregulates protein folding chaperones and proteases to resolve the consequences of a mitonuclear protein imbalance. In the early stages of aging, the UPRᵐᵗ appears to be upregulated in response to age-related mitochondrial proteostatic stress. In aged senescent cells however, the UPRᵐᵗ response is blunted. There is cross-species evidence that induction of the UPRᵐᵗ through moderate-intensity exercise or through genetic disruption of the mitochondrial translation machinery will act as a hormetic - resulting in health benefits in the long term. Caenorhabditis elegans longevity models demonstrate that a reduction in mitochondrial ribosomal protein (Mrp) gene expression or disturbed mitochondrial translation will function as a hormetic. The disruption of the mitochondrial ribosome leads to a mitonuclear protein imbalance, invokes the nematode UPRᵐᵗ, which then robustly extends C. elegans lifespan and health span. To determine whether the hormetic effects of mild mitochondrial ribosome disruption can be recapitulated in a mammalian model, this thesis tests a C57/BL6/NTaconic mouse model altered in the germline to have reduced Mrpl54 expression through heterozygous mutation. Mice were metabolically tested at ages 6-, 18-, and 24-months and followed through their natural lifespan to determine whether reduction in the expression of a critical Mrp (Mrpl54) impacts lifespan or metabolic health span. While Mrpl54 mRNA expression was ~50% of wildtype in all Mrpl54⁺ᐟ⁻ tissues tested, there were no differences observed in metabolic health with age or lifespan in either male or female mice. Cultured Mrpl54⁺ᐟ⁻ primary myoblasts had lower absolute levels of nDNA- and mtDNA-encoded respiratory complex subunits relative to wildtype; however, the ratio between nDNA- and mtDNA-encoded protein subunits remained like wildtype. Further testing of the model revealed that Mrpl54⁺ᐟ⁻ males had weaker grip strength by age 12-months, which was also found in the data from multiple heterozygous Mrp (Mrp⁺ᐟ⁻) mouse models available at the International Mouse Phenotyping Consortium. 12-month-old Mrpl54⁺ᐟ⁻ males displayed reduced tetanic force and better fatigue recovery in ex vivo skeletal muscles, and the transmission electron micrographs of skeletal muscle sarcomeres revealed an early aging phenotype. Unlike the C. elegans reduced Mrp longevity model, reduced expression of a critical Mrp did not result in lifespan or metabolic health span benefits in a mouse model. In contrast, the Mrpl54⁺ᐟ⁻ male model showed evidence of premature skeletal muscle aging. While the results of this research do not support the role of Mrpl54 reduced expression in mammalian lifespan or health span extension, they do point to a premature aging phenotype for certain muscle parameters that may be relevant to people living with heterozygous mitochondrial protein mutations. Typically, these individuals are regarded as carriers and free of phenotype associated with their mitochondrial protein mutation. The results in this thesis suggest that those with a heterozygous mitochondrial protein gene mutation may manifest a phenotype as they grow older and are less resilient to external or internal challenges.